Drug intelligence / Profile preview

EXP039

Development stage: Unknown
Modality: Small Molecules
Administration: Ophthalmic

Overview

EXP039 is an ophthalmic solution currently undergoing a Phase 1/2 crossover study to evaluate its safety, pharmacodynamics, and efficacy. It is being investigated for the treatment of myopia and hyperopia, with its primary mechanism of action involving the induction of pupillary miosis to improve uncorrected distance visual acuity.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on EXP039.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXP039.

Explore the full profile